ABSTRACT
BACKGROUND:
Gastric cancer is known as the fourth most common cancer. Current treatments for cancer have damaged the sensitive tissues of the healthy body, and in many cases, cancer will be recurrent. Therefore, need for treatments that are more effective is well felt. Researchers have recently shifted their attention towards antipsychotic dopamine antagonists to treat cancer. The anticancer activities of aripiprazole remain unknown.
OBJECTIVE:
This study aimed to evaluate the efficacy and safety of aripiprazole on gastric cancer and normal cell lines.
METHODS:
In this regard, the cytotoxicity and genotoxicity of aripiprazole were investigated in MKN45 and NIH3T3 cell lines by methyl tetrazolium assay and on peripheral blood lymphocytes by micronucleus assay. For this purpose, cells were cultured in 96 wells plate. Stock solutions of aripiprazole and cisplatin were prepared. After cell incubation with different concentrations of aripiprazole (1, 10, 25, 50, 100 and 200 μL), methyl tetrazolium solution was added. For micronucleus assay fresh blood was added to RPMI culture medium 1640 supplemented, and different concentrations of aripiprazole (50, 100 and 200 μL) were added.
RESULTS:
The finding of present study showed that the IC50 of aripiprazole in the cancer cell line (21.36 μg/mL) was lower than that in the normal cell line (54.17 μg/mL). Moreover, the micronucleus assay showed that the frequency of micronuclei of aripiprazole at concentrations below 200 μM was much less than cisplatin.
CONCLUSION:
Aripiprazole can be a good cytotoxic compound and good candidate for further studies of cancer therapy.
HEADINGS:
Stomach neoplasms; Dopamine antagonists; Aripiprazole, therapeutic use; Tetrazolium salts; Micronucleus tests; Mutagenicity tests
Thumbnail
Thumbnail
Thumbnail
